Posted On: 10/09/2014 10:19:02 AM
Post# of 30066
Jason Napadano is giving AMBS some love on Twitter:
$AMBS expanding data to n=140 should allow for CLIA and potential FDA submission on LymPro in 2015. RUO sales efforts start in later this Q.
V1 accuracy rate of 87% opens doors to biomarker monitoring on patients. V2 sensitivity of 90% allows for effective screening mechanism.
RUO market is pretty substantial for $AMBS. BP's looking to screen for enrollment in a p2 AD study can save millions by using LymPro.
My most recent $AMBS article highlights why these data this morning are so important for LymPro >> http://bionapcfa.blogspot.com/2014/09/amarant...ights.html …
Great news from $AMBS this morning on positive LP-002 data w/ LymPro. Company expects to launch LymPro into the RUO market before year-end.
$AMBS expanding data to n=140 should allow for CLIA and potential FDA submission on LymPro in 2015. RUO sales efforts start in later this Q.
V1 accuracy rate of 87% opens doors to biomarker monitoring on patients. V2 sensitivity of 90% allows for effective screening mechanism.
RUO market is pretty substantial for $AMBS. BP's looking to screen for enrollment in a p2 AD study can save millions by using LymPro.
My most recent $AMBS article highlights why these data this morning are so important for LymPro >> http://bionapcfa.blogspot.com/2014/09/amarant...ights.html …
Great news from $AMBS this morning on positive LP-002 data w/ LymPro. Company expects to launch LymPro into the RUO market before year-end.
(0)
(0)
